Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients

Open access
Morrisett, Joel D., Abdel-Fattah, Ghada, Hoogeveen, Ron, Mitchell, Eddie, Ballantyne, Christie M., Pownall, Henry J., Opekun, Antone R., Jaffe, Jonathon S., Oppermann, Suzanne, Kahan, Barry D. · 2002 · Journal of Lipid Research

Abstract

Sirolimus (Rapammune, rapamycin, RAPA) is a potent immunosuppressive drug that reduces renal transplant rejection. Hyperlipidemia is a significant side effect of sirolimus treatment, and frequently leads to cardiovascular disease. This study was undertaken to determine the repeatability, reversibility, and dose dependence of the plasma lipid and apolipoprotein altering effects of sirolimus, and to elucidate the mechanism by which sirolimus induces hypertriglyceridemia in some renal transplant patients. Six patients with renal allografts maintained on cyclosporine A and prednisone were selected on the basis of their previous hyperlipidemic response to short term (14 days) sirolimus administration. For longer-term treatment, each patient was started on 10 mg/day sirolimus and continued as tolerated for 42 days to reinduce hyperlipidemia. Timed blood samples were analyzed for lipid, apolipoprotein, and sirolimus levels. During sirolimus administration, mean total plasma cholesterol increased from 214 mg/dl to 322 mg/dl (+50%; range 25-92%); LDL-cholesterol levels followed a similar pattern. Mean triglyceride level rose from 227 to 432 mg/dl (+95%; range 9-254%). ApoB-100 concentration rose from 124 to 160 mg/dl (+28%; P < 0.05). ApoC-III level increased from 28.9 to 55.5 mg/dl, +92%; (P < 0.013). These lipid and apolipoprotein changes were found to be repeatable, reversible, and dose dependent. [(13)C(4)]palmitate metabolic studies in four patients with hypertriglyceridemia indicated that the free fatty acid pool was expanded by sirolimus treatment (mean = 42.3%). Incorporation of [(13)C(4)]palmitate into triglycerides of VLDL, IDL, and LDL was decreased 38.3%, 42,1%, and 38.4%, respectively, by sirolimus treatment of these patients. These results suggest that sirolimus alters the insulin signaling pathway so as to increase adipose tissue lipase activity and/or decrease lipoprotein lipase activity, resulting in increased hepatic synthesis of triglyceride, increased secretion of VLDL, and increased hypertriglyceridemia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1194/jlr.m100392-jlr200

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 (A-F, parts labeled I) Measurement of sirolimus dosages during the 8 week protocol of the later longer term treatment (42 days) on sirolimus and followup (day 56). Sirolimus trough levels were measured on whole blood samples. Measurements in patients: (A, part I) WAS-1/2; (B, part I) WAS-3/4; (C, part I) WAS-5/6; (D, part I) WAS-7/8; (E, part I) WAS-9/10; (F, part I) WAS-11/12. (A-F, parts labeled II) Measurement of weekly lipid profiles during the 8 week protocol of the longer term treatment (42 days) on sirolimus and followup (day 56). Plasma samples were prepared by centrifugation of venous blood collected after 12 h fasting and plasma lipid levels were measured as described in the text. Measurements in patients: (A, part II) WAS-1/2; (B, part II) WAS-3/4; (C, part II) WAS-5/6; (D, part II) WAS-7/8; (E, part II)
Fig. 1 (A-F, parts labeled I) Measurement of sirolimus dosages during the 8 week protocol of the later longer term treatment (42 days) on sirolimus and followup (day 56). Sirolimus trough levels were measured on whole blood samples. Measurements in patients: (A, part I) WAS-1/2; (B, part I) WAS-3/4; (C, part I) WAS-5/6; (D, part I) WAS-7/8; (E, part I) WAS-9/10; (F, part I) WAS-11/12. (A-F, parts labeled II) Measurement of weekly lipid profiles during the 8 week protocol of the longer term treatment (42 days) on sirolimus and followup (day 56). Plasma samples were prepared by centrifugation of venous blood collected after 12 h fasting and plasma lipid levels were measured as described in the text. Measurements in patients: (A, part II) WAS-1/2; (B, part II) WAS-3/4; (C, part II) WAS-5/6; (D, part II) WAS-7/8; (E, part II)CC-BY · From the PDF
WAS-9/10; (F, part II) WAS-11/12. (A-F, parts labeled III) Measurement of weekly apolipoprotein profiles during the 8 week protocol of the longer term treatment (42 days) on sirolimus and followup (day 56). Plasma samples were prepared by centrifugation of venous blood collected after 12 h fasting and weekly plasma apolipoprotein levels were measured as described in the text. Measurements in patients: (A, part III) WAS-1/2; (B, part III) WAS-3/4; (C, part III) WAS-5/6; (D, part III) WAS-7/8; (E, part III) WAS-9/10; (F, part III) WAS-11/12.
WAS-9/10; (F, part II) WAS-11/12. (A-F, parts labeled III) Measurement of weekly apolipoprotein profiles during the 8 week protocol of the longer term treatment (42 days) on sirolimus and followup (day 56). Plasma samples were prepared by centrifugation of venous blood collected after 12 h fasting and weekly plasma apolipoprotein levels were measured as described in the text. Measurements in patients: (A, part III) WAS-1/2; (B, part III) WAS-3/4; (C, part III) WAS-5/6; (D, part III) WAS-7/8; (E, part III) WAS-9/10; (F, part III) WAS-11/12.CC-BY · From the PDF
Fig. 2 Percent atom enrichment in the free fatty acid fractions of plasma collected during/after infusion of [ 13 C 4]palmitate into four renal transplant patients before (odd number, solid lines) and after 6 weeks of (even number, dashed lines) sirolimus treatment. The integrated area under each curve is tabulated in Table 6.
Fig. 2 Percent atom enrichment in the free fatty acid fractions of plasma collected during/after infusion of [ 13 C 4]palmitate into four renal transplant patients before (odd number, solid lines) and after 6 weeks of (even number, dashed lines) sirolimus treatment. The integrated area under each curve is tabulated in Table 6.CC-BY · From the PDF
Fig. 3 Incorporation of [ 13 C 4]palmitate into triglycerides of VLDL, IDL, and LDL of patient WAS-7/8 before (solid lines) and after 6 weeks of (dashed lines) sirolimus treatment.
Fig. 3 Incorporation of [ 13 C 4]palmitate into triglycerides of VLDL, IDL, and LDL of patient WAS-7/8 before (solid lines) and after 6 weeks of (dashed lines) sirolimus treatment.CC-BY · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Research works printed but not linked: 2

  1. Mac Donald, 2001, The Rapamune Global Study Group: a randomized, placebo-controlled trial of rapammune in primary renal allograft recipients, Transplantation., 71, 271
  2. Morrisett, 2001, Effect of rapamycin on free fatty acid metabolism in renal transplant patients, Arterioscler. Thromb. Vasc. Biol., 21, 654

Cited by

See all 295

Metadata

Authors
Morrisett, J. D., Abdel-Fattah, G., Hoogeveen, R., Mitchell, E., Ballantyne, C. M., Pownall, H. J., Opekun, A. R., Jaffe, J. S., Oppermann, S., & Kahan, B. D.
Affiliations
  • Baylor College of Medicine (US)
  • The University of Texas Health Science Center at Houston (US)
Corresponding author
Morrisett, Joel D.
Venue
Journal of Lipid Research
Publisher
Elsevier BV
Published
2002-08
Volume
43
Issue
8
Pages
1170-1180
ISSN
0022-2275 (ISSN-L)
OpenAlex
W1783019770
Cited by
295
References
38
Citations by year
2026: 6 · 2025: 4 · 2024: 9 · 2023: 10 · 2022: 15 · 2021: 10 · 2020: 12 · 2019: 6 · 2018: 12 · 2017: 16 · 2016: 20 · 2015: 14 · 2014: 23 · 2013: 14 · 2012: 22
FWCI
6.57
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Lipid Research (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • U.S. Public Health Service (DL 38016)
  • National Heart, Lung, and Blood Institute (HL-07812, T32HL007812)
Topics
  • Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
Keywords
rapamycin, kidney transplantation, hyperlipidemia, hypertriglyceridemia, plasma lipids, apolipoproteins, apolipoprotein B-100, apolipoprotein C-III, fatty acid metabolism, palmitate incorporation, lipoprotein lipase, adipose tissue lipase, insulin signaling, cyclosporine
MeSH terms
Adult, Cholesterol, Fatty Acids, Nonesterified, Female, Humans, Immunosuppressive Agents, Lipoproteins, Male, Middle Aged, Triglycerides, Kidney Transplantation, Sirolimus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. https://app.cochat.ai/papers/10.1194/jlr.m100392-jlr200
The paper
Morrisett, J. D., Abdel-Fattah, G., Hoogeveen, R., Mitchell, E., Ballantyne, C. M., Pownall, H. J., Opekun, A. R., Jaffe, J. S., Oppermann, S., & Kahan, B. D. (2002). Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. Journal of Lipid Research. https://doi.org/10.1194/jlr.m100392-jlr200

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.